Decreased Creatinine Clearance Which May Be Observed during Prostaglandin E 1 Therapy: Is it Reversible with Discontinuation of Therapy?

Abstract

A study was carried out in four patients with nephrotic diabetic nephropathy in order to determine if decreased creatinine clearance observed during prostaglandin E₁ therapy was reversible on discontinuation of therapy. The patients received 40 μg prostaglandin E₁ intravenously twice daily for 4 weeks and creatinine clearance and daily excretion of urinary protein were measured immediately before, during and 2 weeks after therapy. Total serum protein and serum albumin were also determined. There was a significant decrease in creatinine clearance during therapy and after therapy clearance increased but not significantly. It is concluded that decreased creatinine clearance during prostaglandin E₁ therapy has a partial reversibility on discontinuation of the treatment.

Keywords

nephrotic diabetic nephropathy creatinine clearance total serum protein serum albumin urinary protein

Get full access to this article

View all access options for this article.

References

Rizzetto

Canese

Arico

: Immunofluorescence detection of new antigen – antibody system (delta/anti-delta) associated to hepatitis B virus in liver and serum of HBsAg carriers. Gut 1977; 18: 997–1003.

Rizzetto

: The delta agent. Hepatology 1983; 3: 729–737.

Rizzetto

Shih

Gerin

: The hepatitis B virus-associated delta antigen: isolation from liver, development of solid-phase radioimmunoassays for delta antigen and anti-delta and partial characterization of delta antigen. J Immunol 1980; 125: 318–324.

Rizzetto

Canese

Gerin

: Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. J Infect Dis 1980; 141: 590–603.

Ichimura

Tamura

Tsubakio : Influence of hepatitis delta virus superinfection on the clearance of hepatitis B virus (HBV) markers in HBV carrier in Japan. J Med Virol 1988; 26: 49–55.

Krogsgaard

Kryer

Aldershvide

: The Copenhagen Hepatitis Acta Programme (1987): delta-infection and suppression of hepatitis B virus replication in chronic HBsAg carriers. Hepatology 1987; 7: 42–45.

Smedile

Dentico

Zanetti

: Infection with delta antigen in chronic HBsAg carriers. Gastroenterology 1981; 81: 992–997.

Rizzetto

Purcell

Gerin

: Epidemiology of HBV-associated delta agent: geographical distribution of anti-delta and prevalence in polytransfused HBsAg carriers. Lancet 1980; i: 1215–1218.

Mori

Ito

Yokosuka

: Delta infection in Japan: immunohistological and immunoelectron microscopic study of delta antigen in liver tissue. J Gastroenterol Hepatol 1986; 1: 33–38.

10.

Caredda

Antinori

: Course and prognosis of acute HDV hepatitis. In: Hepatitis Delta Virus and Its Infection ( Rizzetto

Gerin

Purcell

, eds). New York: Alan R. Liss, 1987; pp 267–276.

11.

Juji

Yokochi

: Hemagglutination for erythrocyte coated with specific antibody for detection of Australian antigen. Jpn J Exp Med 1969; 39: 615–620.

12.

Zehr

: Use of hydrogen peroxide – egg albumin to eliminate non-specific staining in immunoperoxidase techniques. J Histochem Cytochem 1978; 26: 415–416.

13.

Graham

Karnovsky

: Glomerular permeability: ultrastructural cytochemical studies of peroxidase on protein traces. J Exp Med 1966; 124: 1123–1133.

14.

Smedile

Farci

Verme

: Influence of delta infection on severity of hepatitis B. Lancet 1982; i: 945–947.

15.

Tamura

Ichimura

Koda

: Hepatitis delta virus infection in different time periods in Japan. J Gastroenterol Hepatol 1990; 5: 407–410.

16.

Rizzetto

Morello

Mannucci

: Delta infection and liver disease in hemophilic carriers of hepatitis B surface antigen. J Infect Dis 1982; 145: 18–12.

17.

Ponzetto

Seeff

Buskell-Bales

: Hepatitis B markers in United States drug addicts with special emphasis on the delta hepatitis virus. Hepatology 1984; 4: 1111–1115.